Navigation Links
Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Date:1/28/2008

FAIRFIELD, N.J., Jan. 28 /PRNewswire/ -- Arno Therapeutics, Inc., a privately held drug development company, announced that it has entered into worldwide, exclusive license agreements with The Ohio State University ("OSU") for the rights to commercially develop novel, orally available, targeted therapies for cancer.

Pursuant to the license agreements, Arno acquired the rights to several small molecules for the treatment of cancer, including OSU-03012 (NSC D728209) and OSU-HDAC42 (NSC D736012). Both agents were developed by Ching-Shih Chen, Ph.D., a professor of pharmacy and internal medicine at Ohio State and a researcher in OSU's Comprehensive Cancer Center.

OSU-03012 is a PDK-1 inhibitor that targets the Akt pathway, and also possesses activity in alternate pathways to target apoptosis and angiogenesis. Preclinical data have demonstrated activity in multiple tumor types and synergistic activity with other agents including Avastin(R), Herceptin(R), Tarceva(R), Gleevec(R) and tamoxifen.

OSU-HDAC42 is a broad spectrum histone-deacetylase inhibitor which possesses additional mechanisms as well. In preclinical studies OSU-HDAC42 has demonstrated greater potency and a competitive profile in solid and liquid tumors when compared with vorinostat (SAHA), the leading marketed compound in the class.

"We are extremely pleased to be developing these two exciting and novel molecules for the treatment of cancer patients," said Scott Z. Fields, M.D., President and CMO of Arno. "We look forward to moving these molecules into the clinic and to hopefully bringing their benefits to patients who need them as soon as possible."

"The out-licensing of these two very important molecularly targeted oncology compounds to Arno Therapeutics is a significant milestone for Ohio State," said Dr. Michael Caligiuri, director of the Ohio State University Comprehensive Cancer Center and CEO of The James Cancer Hospital and Solove Research Institute. "These are the first two molecules for cancer treatment created entirely at OSU that will be brought into the cancer clinic."

Pursuant to the terms of the license agreement, Arno will pay development based milestones and royalties based on sales of the licensed products.

Arno plans to initiate Phase I clinical trials for both OSU-03012 and OSU- HDAC42 in 2009.

About Arno Therapeutics, Inc.

Arno Therapeutics is a biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno is initially focusing its efforts on developing its lead compound, DB-67, a novel anti-cancer agent. DB-67 is a third generation campthothecin analogue that has demonstrated high potency and significantly improved pharmacokinetic properties as demonstrated by greater stability of the active lactone form in pre-clinical studies as compared with second-generation products. Arno is currently enrolling patients in a Phase I clinical trial. A key component of the Company's strategy is to acquire global rights to additional product candidates for the treatment of cancer while continuing to use its technology to develop and commercialize new products and line extensions. For more information on Arno please visit http://www.arnothera.com.

Contact:

Scott Z. Fields, M.D.

President and CMO

Arno Therapeutics, Inc.

(862) 703-7170

info@arnothera.com

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, and product pricing and third party reimbursement. We undertake no obligation to update any forward-looking statement contained in this press release, except as required by law.


'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
4. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
5. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
6. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
7. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
8. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
9. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
10. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
11. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):